<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047642</url>
  </required_header>
  <id_info>
    <org_study_id>AFI_01</org_study_id>
    <nct_id>NCT03047642</nct_id>
  </id_info>
  <brief_title>Validation of Promising Biomarker Assays to Assess Their Diagnostic Performance Characteristics</brief_title>
  <official_title>Validation of Promising Biomarker Assays to Assess Their Diagnostic Performance Characteristics in Africa and Latin America</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malawi Epidemiology and Intervention Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Infectologia Evandro Chagas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche Médicale de Lambaréné</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to evaluate the performance characteristics of rapid tests to differentiate&#xD;
      bacterial from non-bacterial infection in febrile adults and children presenting at OPDs&#xD;
      (outpatient departments) i.e.(&quot;fever triage assays&quot;) in three LMICs. The evaluation will&#xD;
      include a different commercial biomarker combinations as well as individual biomarkers to&#xD;
      assess their individual or combined value in the target population. Markers will be evaluated&#xD;
      onsite in ELISA or RDT format, as appropriate. Further, this study aims to contribute to a&#xD;
      centralized biobank of well-characterized specimens for use by IVD companies and academic&#xD;
      institutions for the development and evaluation of emerging assays.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2017</start_date>
  <completion_date type="Actual">November 27, 2019</completion_date>
  <primary_completion_date type="Actual">October 27, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic sensitivity and specificity to determine bacterial infections compared to clinical and microbiological results aggregated in a study database.</measure>
    <time_frame>1year</time_frame>
    <description>Microbiological testing (blood culture positive/negative, malaria pos/neg, S. Tyhpi RDT pos/neg) and clinical assessments of symptoms (respiratory, gastro, no foci) will be recorded and reviewed by a clinical panel upon completion of the study to assign a final category (bacterial or non-bacterial). These categories are used in the evaluation of the biomarker assays to evaluate their performance in differentiating bacterial from non-bacterial infections. Where applicable, the same categories will be used to determine the area under the curve by employing receiver operator characteristics (ROC) analysis of quantitative markers.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">2000</enrollment>
  <condition>Acute Febrile Illnesses</condition>
  <arm_group>
    <arm_group_label>Malawi febrile patients</arm_group_label>
    <description>Children and adults with fever presenting at the outpatient department</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brazil febrile patients</arm_group_label>
    <description>Children and adults with fever presenting at the outpatient department</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabon febrile patients</arm_group_label>
    <description>Children with fever or with a recent history of fever presenting at the outpatient department</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biomarker assay</intervention_name>
    <description>There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients</description>
    <arm_group_label>Brazil febrile patients</arm_group_label>
    <arm_group_label>Gabon febrile patients</arm_group_label>
    <arm_group_label>Malawi febrile patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples of whole blood, plasma, serum and urine are stored to establish a biobank of&#xD;
      characterized samples for further development and testing of diagnostic tools for&#xD;
      differential diagnosis of multiple febrile diseases in endemic areas.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any non-severely ill subject presenting with acute fever defined as: temperature of more&#xD;
        than 38°C at initial evaluation of less than 7 days of symptoms at presentation.&#xD;
&#xD;
        For recruitment purposes, subjects will be classified into two groups:&#xD;
&#xD;
          -  Children 2-17 years of age&#xD;
&#xD;
          -  Adults 18-65 years of age&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Any non-severely ill subject presenting with acute fever defined as: temperature of more&#xD;
        than 38°C at initial evaluation of less than 7 days of symptoms at presentation.&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Children 2-17 years of age&#xD;
&#xD;
          -  Adults 18-65 years of age&#xD;
&#xD;
          -  Signed written informed consent for study participation. For recruitment purposes,&#xD;
             subjects will be classified into two groups, children and adults. For children, age &gt;2&#xD;
             years is the minimum cut-off, based on the amount of blood volume to be obtained in&#xD;
             the study. WHO guidelines for allowable blood volume in 24 hours recommend that no&#xD;
             more than 1-5% of total blood volume (75-80 ml/kg for older children) be obtained.&#xD;
             Applying the average weight of a 2 year old toddler =12 kg, the allowable blood volume&#xD;
             to be drawn in 24 hours at 1-5% of the total blood volume is 9.6 - 48 mL .&#xD;
&#xD;
        For minors, caregivers will provide informed consent. Documented assent for children of 12&#xD;
        to 16 years of age will be required for their participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are felt to be in critical condition (based on clinician assessment or&#xD;
             the presence of any general signs of critical illness as defined by WHO guidelines&#xD;
             (for children: extensive vomiting, active seizure or recent history of seizures,&#xD;
             altered mentation, inability to feed, or any of the severe IMNCI classifications; for&#xD;
             adults: impending airway obstruction, central cyanosis, severe respiratory distress,&#xD;
             feeble pulse, active seizure or recent history of seizures, or unconsciousness)&#xD;
             because the target population for the study is non-severe febrile subjects.&#xD;
&#xD;
          -  Subjects can only be enrolled once into the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Nacional de Infectologia Evandro Chagas - Fiocruz (INIEC)</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CERMEL</name>
      <address>
        <city>Lambaréné</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karonga Prevention Study</name>
      <address>
        <city>Chilumba</city>
        <state>Karonga District</state>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Gabon</country>
    <country>Malawi</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarker</keyword>
  <keyword>low and middle income countries</keyword>
  <keyword>fever</keyword>
  <keyword>antimicrobial resistance</keyword>
  <keyword>diagnostic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>As appropriate data will be made available to the scientific community and/or commercial partners to support product development activities.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

